Top Abstract Purchase Preview Related
Home
>
Node
>
Subnode

Formulation composition of botulinum toxins in clinical use

Pickett, A.; Perrow, K.

Journal of Drugs in Dermatology Jdd 9(9): 1085-1091

2010

ISSN/ISBN: 1545-9616
PMID: 20865839
Document Number: 12694
The use of botulinum toxin (BoNT) has now become the treatment of choice for a range of debilitating neuromuscular diseases and for aesthetic medicine. BoNT products are licensed as prescription-only medicines by the health authorities of each country in which they are approved. The authors describe here the current status with regard to BoNT formulations and detail more precisely what is in each product. These data have been presented previously, in a fragmented way, in papers that discuss characteristics of the BoNT products but not the formulations in detail. This information is essential for clinicians in order to enable informed decisions about which products they wish to use clinically. The authors have also examined developments that are either in progress or likely to occur, based on currently available information.

Document emailed within 1 workday
Secure & encrypted payments

Formulation composition of botulinum toxins in clinical use

Heegaard, N.H.H.; Beyer, N.H.; Kogutowska, E.; Tanassi, J.T.; Jensen, S.ør.M.; Andresen, K.; Christensen, J.J.ør. 2005: Botulinum and ricin toxins Ugeskrift for Laeger 167(36): 3387-3389
Soinila, S.; Haanpää, M. 2011: Botulinum toxins for pain Duodecim; Laaketieteellinen Aikakauskirja 127(22): 2425-2430
Brin, M.F.; Tan, K.; Gallagher, C. 2009: Differences in botulinum toxins: time to end the confusion Journal of Cosmetic and Laser Therapy 11(3): 180-181
Levdikova, G.A.; Klimacheva, L.V.; Ispolatovskaia, M.V.; Bulatova, T.I.; Anisimova, L.I. 1982: Characteristics of the activation of type E. Cl. botulinum toxins Zhurnal Mikrobiologii Epidemiologii i Immunobiologii 4: 77-81
Beer, K. 2010: Cost effectiveness of botulinum toxins for the treatment of depression: preliminary observations Journal of Drugs in Dermatology: Jdd 9(1): 27-30
Zworska, J. 1972: Susceptibility of mice to tetanus and botulinum toxins as related to body weight and sex Medycyna Doswiadczalna i Mikrobiologia 24(4): 299-306
Uchiyama, T. 2002: Research on superantigenic toxins integrating bacteriology, immunology, bacterial toxins, and clinical infections diseases Nihon Saikingaku Zasshi. Japanese Journal of Bacteriology 57(4): 563-579
Tsarapkin, V.P. 1971: Preparation of purified sorbed botulinum toxoid type F. II. Activity of crude toxins and toxoids Zhurnal Mikrobiologii Epidemiologii i Immunobiologii 48(11): 105-108
Cohen, J.L. 2014: Scientific skepticism and new discoveries: an analysis of a report of zinc/phytase supplementation and the efficacy of botulinum toxins in treating cosmetic facial rhytides, hemifacial spasm and benign essential blepharospasm Journal of Cosmetic and Laser Therapy 16(5): 258-262
Alouf, J.E. 1981: Thiol-dependent cytolytic bacterial toxins: streptolysin O and prominent toxins Archives de l'Institut Pasteur de Tunis 58(3): 355-373
Tjaberg, T.B. 1974: Proteases of Clostridium botulinum. VI. the role of trypsin, Clostridium botulinum proteases and protease inhibitors in the formation and activation of toxin in growing cultures of Clostridium botulinum Acta Veterinaria Scandinavica 15(4): 487-506
Cibis, G.W.; Waeltermann, J. 1985: Botulinum isn't just a poison anymore. Botulinum toxin in treatment of strabismus and essential blepharospasm Missouri Medicine 82(3): 145-147
Glezerov, V.Z. 1971: Effect of microbial toxins on the permeability of the blood-tissue barrier. II. Formation of a non-immunological tolerance to the action of toxins on the permeability of the histohematic barrier of mouse kidney Zhurnal Mikrobiologii Epidemiologii i Immunobiologii 48(10): 121-124
2003: Sublingual selegiline: new formulation. New formulation: new risk of oral adverse effects Prescrire International 12(67): 179
2002: Tobramycin for nebulisation: new formulation. A high price for a small improvement in formulation Prescrire International 11(62): 177-178
Truong, D.D.; Stenner, A.; Reichel, G. 2009: Current clinical applications of botulinum toxin Current Pharmaceutical Design 15(31): 3671-3680
Ubysz-Jerzmanowska, K. 1972: Effect of diphtheria toxins on guinea pig macrophages. 3. Lysosomes of peritoneal macrophages subjected to action of diphtheria toxins Medycyna Doswiadczalna i Mikrobiologia 24(3): 201-206
Rudoĭ, B.A.; Telitsyn, A.M.; Bakulina, L.V.; Evstigneev, V.I. 1998: Extrachromosomal genetic elements of Clostridium botulinum. II. Isolation and analysis of DNA from bacteriophages of Clostridium botulinum types C and a Molekuliarnaia Genetika Mikrobiologiia i Virusologiia 4: 22-28
Wang, Y.J.; Leesman, G.D.; Lipstein, M.E.; Basch, H.I.; Monkhouse, D.C. 1984: Optimization of autoclave cycles and selection of formulation for parenteral products, Part III: Effect of formulation variables on sporicidal kinetics Journal of parenteral science and technology: a publication of the Parenteral Drug Association 38(2): 78-82
Palyza, V. 1972: Chromatography of amanita toxins. II. New method for the identification of amanita toxins by means of thin-layer chromatography Journal of Chromatography 64(2): 317-325